Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 26, 2023

Discussing AI and Digitalization with Alessandro Zannini (INTERPHEX 2023)

Alessandro Zannini, sales director, engineering division, Stevanato Group, discusses artificial intelligence and digitalization in the pharma field.

Alessandro Zannini, sales director, engineering division, Stevanato Group, discusses artificial intelligence and digitalization in the pharma field and addresses challenges associated with with visual inspection, assembly, and secondary packaging processes for pharma companies.

For more INTERPHEX 2023 video content, check this page for updates.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.